Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
0.8979
-0.0291 (-3.14%)
At close: Oct 5, 2026, 4:00 PM EDT
0.8900
-0.0079 (-0.88%)
Pre-market: Oct 6, 2026, 4:07 AM EDT
CNTB Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, CNTB stock has a consensus rating of "Strong Buy" and an average price target of $5.88. The average 1-year stock price forecast is 554.86% higher than the current stock price, while the lowest is $4.00 (+345.48%) and the highest is $9.00 (+902.34%).
Price Target: $5.88 (+554.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CNTB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 6 | 7 | 7 | 7 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 | Buy | Reiterates | $7 | +679.60% | Oct 2, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $6 | Buy | Reiterates | $6 | +568.23% | Oct 1, 2026 |
| Lake Street | Lake Street | Buy Maintains $9 | Buy | Maintains | $9 | +902.34% | Sep 30, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 → $5 | Buy | Reiterates | $8 → $5 | +456.85% | Sep 22, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $6 → $4 | Buy | Reiterates | $6 → $4 | +345.48% | Sep 16, 2026 |
Financial Forecast
Revenue This Year
7.29M
from 64.00K
Increased by 11,292.49%
Revenue Next Year
15.63M
from 7.29M
Increased by 114.35%
EPS This Year
-0.97
from -1.00
EPS Next Year
-0.70
from -0.97
EPS and Forward PE are based on non-GAAP adjusted numbers.